Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK's new drug application (NDA) for Blenrep ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...

The approval sets the stage for iRhythm to work towards a reimbursement decision for the system with the Japanese MHLW.

King of Prussia, Pennsylvania Monday, September 16, 2024, 17:00 Hrs [IST] ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved for GSK’s Nucala (mepolizumab) for the treatment of adults ...

Rhythm Technologies announced that it received approval in Japan for its Zio long-term continuous monitoring (LTCM) system.

Osaka Metropolitan University researchers analyzed the incidence in Japan of COVID-19-associated pulmonary aspergillosis ...

Investigating Japanese longevity reveals the impact of lifestyle medicine and government strategies on health, offering ...

(RTTNews) - iRhythm Technologies, Inc. (IRTC), a digital health care company, Wednesday said it has received approval from the Japanese ...

CSL and self-amplifying mRNA (sa-mRNA) pioneer Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) granted approval and authorization for their updated ...